Clinical Laserthermia Systems AB (publ) announces that the company has received market approval for its entire portfolio of TRANBERG® Thermal Therapy products in Singapore for thermal ablation of soft tissue pathological lesions for tumor control, symptomatic relief and restoring of physiological functions in the prostate and liver. The market approval for CLS portfolio of TRANBERG Thermal Therapy Systems by HSA in Singapore constitutes a significant milestone in the company's global expansion and enables CLS to initiate the process of commercialization throughout the Singapore market. In addition, the approval, combined with early successful treatment outcomes, allows for a wider commercialization in the Asia-Pacific region.

The commercial start in Singapore & expansion into the Asia-Pacific region is being carried out through CLS joint venture CLS Asia Pacific PTE. LTD headquartered in the Reublic of Singapore. The TRANBERG Thermal Therapy System now enters into a limited market release at selected medical centers across Singapore.